397 related articles for article (PubMed ID: 26873369)
21. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
22. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
23. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
Douros A; Abrahami D; Yin H; Yu OHY; Renoux C; Hudson M; Azoulay L
Epidemiology; 2018 Nov; 29(6):904-912. PubMed ID: 30028343
[TBL] [Abstract][Full Text] [Related]
24. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
Meduru H; Wang YT; Tsai JJ; Chen YC
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.
Cho TP; Long YF; Gang LZ; Yang W; Jun LH; Yuan SG; Hong FJ; Lin W; Liang GD; Lei Z; Jing LJ; Shen GA; Hong SG; Dan W; Ying F; Ke YP; Ying L; Jun F; Tai MX
Bioorg Med Chem Lett; 2010 Jun; 20(12):3565-8. PubMed ID: 20488702
[TBL] [Abstract][Full Text] [Related]
26. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
27. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Gallwitz B
Expert Opin Investig Drugs; 2011 Jun; 20(6):723-32. PubMed ID: 21500969
[TBL] [Abstract][Full Text] [Related]
28. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.
De S; Banerjee S; Kumar SKA; Paira P
Mini Rev Med Chem; 2019; 19(2):88-97. PubMed ID: 29692250
[TBL] [Abstract][Full Text] [Related]
29. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
30. All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.
Yen FS; Chiang JH; Hwu CM; Yen YH; Lin BJ; Wei JC; Hsu CC
BMC Endocr Disord; 2019 Jan; 19(1):3. PubMed ID: 30611254
[TBL] [Abstract][Full Text] [Related]
31. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.
Kushwaha RN; Haq W; Katti SB
Curr Med Chem; 2014; 21(35):4013-45. PubMed ID: 25245373
[TBL] [Abstract][Full Text] [Related]
32. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
33. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
34. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
35. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Fadini GP; Avogaro A
Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
[TBL] [Abstract][Full Text] [Related]
37. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular effects of the DPP-4 inhibitors.
Jose T; Inzucchi SE
Diab Vasc Dis Res; 2012 Apr; 9(2):109-16. PubMed ID: 22337893
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Liu Y; Hu Y; Liu T
Curr Med Chem; 2012; 19(23):3982-99. PubMed ID: 22709010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]